24 November 2015 - The draft guidance gives provisional recommendations on whether paclitaxel, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, trabectedin and gemcitabine hydrochloride should be offered as treatment options for women with ovarian cancer that has returned after prior chemotherapy treatment.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-consults-on-ovarian-cancer-treatments-draft-guidance